VivoSeq
Other

Autonomic Dysreflexia

4

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Autonomic Dysreflexia is an early-stage landscape with 4 programs across 2 companies. The most active players are Pfizer, AbbVie. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

2 programs

Phase 2AbbVie logo

AbbVie

1 program

Approved

Pipeline

Programs by Phase

Preclinical1

Prazosin Hcl

Pfizer

Phase 1
No programs
Phase 21

Fesoterodine

Pfizer

Phase 3
No programs
Approved2

Botox

AbbVie

Mecamylamine

Targacept Inc.

Analysis

Trial Status

5

clinical trials

Completed3 · 60%
Not yet recruiting1 · 20%
Unknown status1 · 20%

Clinical Trials

Trial Activity

Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI
Completed·RRick Hansen Institute·Phase 4·NCT02298660·55 enrolled
NO AD: Use of Nitric Oxide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During Bowel Care Following SCI
Not yet recruiting·SSimon Fraser University·Phase 2·NCT05635851·26 enrolled
Mecamylamine for Autonomic Dysreflexia Prophylaxis
Unknown status·WWayne State University·Phase 4·NCT03914677·5 enrolled
Prazosin Vibrostimulation Autonomic Dysreflexia and Spinal Cord Injury Study
Completed·UUniversity of British Columbia·N/A·NCT00175682·7 enrolled
Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)
Completed·UUniversity of British Columbia·Phase 2·NCT02676154·15 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)